Preview

Current Pediatrics

Advanced search

CEFTRIAXONE EFFICIENCY AMONG PATIENTS, SUFFERING FROM JUVENILE ARTHRITIS AND RECEIVING IMMUNOSUPPRESSIVE THERAPY

Abstract

The article is dedicated to diagnostics and treatment of infectious complications among children with juvenile rheumatoid arthritis, receiving immunosuppressive therapy. The research involves 92 children with different variants of the illness run, who received immunosuppressive therapy. All the patients showed development of the systemic inflammatory response manifestations. The researchers used the definition of the procalcytonine levels as a marker for the bacterial infectiondevelopment. All the patients showed it higher than 0,5 ng/ml, while 7 patients — higher than 10 ng/ml. keeping in mind several courses of the antibacterial therapy in the anamnesis and presence of the combined bacterial infection, ceftriaxone was prescribed to all the children. As a result of the ceftriaxone based therapy, reduction of the clinical and laboratory manifestations of the bacterial infection was noted among more than 90% of patients. The development of the allergic reaction was noted in 1 case, and leukopenia was also found in 1 patient.
Key words: children, juvenile rheumatoid arthritis, ceftriaxone.

About the Authors

A.M. Chomakhidze
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


E.I. Alexeeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


K.B. Isaeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


S.I. Valieva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


T.M. Bzarova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Баранов А.А. Ревматические болезни у детей: проблемы и пути их решения. Вопросы современной педиатрии. 2004; 3 (1): 7–11.

2. Deborah P.M., Symmons. XIV EULAR Congr. Rheumatol. Glasgow, 6-11 June 1999. Speakers abstracts abst.1.1p.

3. Логинова Е.Ю. Взгляд ревматолога интерниста на терминологию классификацию и нозологическую диагностику ювенильного артрита. Научно-практическая ревматология. 2001; 2: 21–30.

4. Насонов Е.Л. Ревматоидный артрит, терапевтические проблемы. Врач. 1999; 5: 7–11.

5. Вест С.Д. Секреты ревматологии. М. – СПб. 1999. 768с.

6. Gilliand W.R. Prophylactic use of antibiotics and immunization in patient with SLE. Ann. of the Rheum. Dis. 2002; 61: 623–625.

7. Bone R.C., Balk R.A., Cerra F.B.et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies is sepsis. The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians. Society of Critical Care Medicine. Chest. 1992; 101 (6): 1644–1655.

8. Gramm H.J., Hannemann L., Reinhart K. Sepsis: a conception in change. Possibilities and limitation of diagnosis based on clinical criteria. Dtsch. Med. Wochenschr. 1995; 120 (14): 498–502.

9. Rangel-Frausto M.S., Pitter D., Costigan M. et al. The natural history of the systemic in inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995; 273 (2): 117–123.

10. Baquero F., Fernandes-Jorge A., Vicente M.F. et al. Diversity analysis of the human faecal flora: a simple method of based on bacterial morphotypes. Microb. Ecol. Heals Dis. 1998; 1 (1): 101–108.

11. Гельфанд Б.Р., Филимонов М.И., Бражник Т.Б., Сергеева Н.А., Бурневич С.З. Прокальцитонин: новый лабораторный диагностический маркер сепсиса и гнойно-септических осложнений в хирургии. Вестник интенсивной терапии. 2003; 1 (2).

12. Клиническое применение прокальцитонина для диагностики и мониторинга скепсиса. Руководство BRAHMS. 2004. 24 с.

13. Korcsowski B., Kovalczyk J.R., Biiark M. Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune disease in children. Pol. Merkur. Lecarski. 2003; 15 (86): 155–157.

14. Алексеева Е.И., Шахбазян И.Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. М.: Novartis Pharma Services Inc. 2002. 127c.


Review

For citations:


Chomakhidze A., Alexeeva E., Isaeva K., Valieva S., Bzarova T. CEFTRIAXONE EFFICIENCY AMONG PATIENTS, SUFFERING FROM JUVENILE ARTHRITIS AND RECEIVING IMMUNOSUPPRESSIVE THERAPY. Current Pediatrics. 2007;6(6):95-100.

Views: 1304


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)